京都医療センター
医療関係者の方
交通アクセスはこちら
病院紹介
外来・入院案内
診療科・部門紹介
地域医療連携
看護部
採用情報
京都医療センター

臨床研究センター

先端医療技術開発研究室メニュー

先端医療技術開発研究室

発表論文等

論文・書籍（2005年4月1日～2024年11月25日）

英文誌141報・邦文誌10報・書籍6件

英文誌 141報（PubMed掲載分のみ）

  • Masunaga N, Ishii M, Oka K, Okamoto K, Yoshida Y, Minami K, Ishigami K, Doi K, Hamatani Y, Yoshizawa T, Ide Y, Fujino A, Iguchi M, Wada H, Hasegawa K, Tsuji H, Esato M, Abe M, Akao M; Fushimi AF Registry Investigators. 10-Year Trends of Antithrombotic Therapy Status and Clinical Outcomes in Patients With Atrial Fibrillation and Renal Dysfunction　- The Fushimi AF Registry. Circ J. 2024 Oct 31. doi: 10.1253/circj.CJ-24-0614. Epub ahead of print.
  • Hamatani Y, Iguchi M, Kato T, Inuzuka Y, Tamaki Y, Ozasa N, Kawaji T, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Kimura T, Ono K, Akao M; Fushimi AF Registry and KCHF Registry investigators. Importance of non-cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction. ESC Heart Fail. 2024 Sep 21. doi: 10.1002/ehf2.15093. Epub ahead of print.
  • Komiyama M, Iguchi M, Wada H, Ikeda T, Dan GA, Hasegawa K. What is the Future Position of Factor XIa Inhibitors for Patients with Atrial Fibrillation? Eur Cardiol. 2024 Jul 1;19:e10. doi: 10.15420/ecr.2023.50.
  • Esato M, Fujino A, Hamatani Y, Yoshizawa T, Ide Y, Ishii M, Iguchi M, Masunaga N, Wada H, Hasegawa K, Tsuji H, Abe M, Akao M. Association of Regression from Sustained to Paroxysmal Atrial Fibrillation with Clinical Outcomes: The Fushimi AF Registry. Am J Cardiol. 2024 Jun 25:S0002-9149(24)00456-9. doi: 10.1016/j.amjcard.2024.06.020. Epub ahead of print.
  • Kishimoto A, Komiyama M, Wada H, Satoh-Asahara N, Yamakage H, Ajiro Y, Aoyama H, Katsuura Y, Imaizumi A, Hashimoto T, Sunagawa Y, Morimoto T, Kanai M, Kakeya H, Hasegawa K. Efficacy of highly bioavailable oral curcumin in asymptomatic or mild COVID-19 patients: a double-blind, randomized, placebo-controlled trial. J Health Popul Nutr. 2024 Jun 24;43(1):93. doi: 10.1186/s41043-024-00584-6.
  • Hamatani Y, Iguchi M, Okamoto K, Nakanishi Y, Minami K, Ishigami K, Ikeda S, Doi K, Yoshizawa T, Ide Y, Fujino A, Ishii M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Akao M. Association of left atrial enlargement with heart failure events in non-valvular atrial fibrillation patients with preserved left ventricular ejection fraction. Eur Heart J Open. 2024 Mar 1;4(2):oeae015. doi: 10.1093/ehjopen/oeae015.
  • Mittal S, Komiyama M, Ozaki Y, Yamakage H, Satoh-Asahara N, Wada H, Yasoda A, Funamoto M, Katanasaka Y, Sunagawa Y, Morimoto T, Akao M, Abe M, Takahashi Y, Nakayama T, Hasegawa K. Impact of smoking initiation age on nicotine dependency and cardiovascular risk factors: a retrospective cohort study in Japan. Eur Heart J Open. 2023 Dec 20;4(1):oead135. doi: 10.1093/ehjopen/oead135.
  • Hamatani Y, Iguchi M, Minami K, Ishigami K, Esato M, Tsuji H, Wada H, Hasegawa K, Ogawa H, Abe M, Lip GYH, Akao M; Fushimi AF Registry investigators. Utility of left ventricular ejection fraction in atrial fibrillation patients without pre-existing heart failure. ESC Heart Fail. 2023 Oct;10(5):3091-3101. doi: 10.1002/ehf2.14500. Epub 2023 Aug 21.
  • Iguchi M, Wada H, Martínez F, Hasegawa K. When Should We Start Sodium-Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention. Eur Cardiol. 2023 Jun 7;18:e41. doi: 10.15420/ecr.2022.62.
  • Komiyama M, Ozaki Y, Wada H, Yamakage H, Satoh-Asahara N, Yasoda A, Sunagawa Y, Morimoto T, Takahashi Y, Hasegawa K. Randomised Double-blind Placebo-Controlled Multicentre Trial for the Effects of Yokukansan in Smokers with Depressive Tendencies. Eur Cardiol. 2023 Apr 25;18:e30. doi: 10.15420/ecr.2023.18.PO13.
  • Ikeda S, An Y, Iguchi M, Ogawa H, Nakanishi Y, Minami K, Ishigami K, Aono Y, Doi K, Hamatani Y, Yoshizawa T, Ide Y, Fujino A, Ishii M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Akao M. Proteinuria is independently associated with heart failure events in patients with atrial fibrillation: The Fushimi AF registry. Eur Heart J Qual Care Clin Outcomes. 2023 Jan 5:qcad001. doi: 10.1093/ehjqcco/qcad001. Epub ahead of print.
  • Hamatani Y, Nishi H, Iguchi M, Esato M, Tsuji H, Wada H, Hasegawa K, Ogawa H, Abe M, Fukuda S, Akao M; Fushimi AF Registry Investigators. Machine Learning Risk Prediction for Incident Heart Failure in Patients With Atrial Fibrillation. JACC Asia. 2022 Nov 1;2(6):706-716. doi: 10.1016/j.jacasi.2022.07.007.
  • Komiyama M, Ozaki Y, Wada H, Yamakage H, Satoh-Asahara N, Yasoda A, Sunagawa Y, Morimoto T, Tamaki S, Masahiro Suzuki, Shibayama T, Kato T, Okada Y, Kita T, Takahashi Y, Hasegawa K. Randomized double-blind placebo-controlled multicenter trial for the effects of a polyherbal remedy, Yokukansan (YiganSan), in smokers with depressive tendencies. BMC Complement Med Ther. 2022 Nov 25;22(1):311. doi: 10.1186/s12906-022-03788-7.
  • Funamoto M, Sunagawa Y, Katanasaka Y, Kato T, Funada J, Ajiro Y, Komiyama M, Akao M, Yasoda A, Yamakage H, Satoh-Asahara N, Wada H, Ikeda Y, Morimoto T, Hasegawa K. Effects of high-absorption curcumin for the prevention of hypertensive heart disease: a double-blind, placebo-controlled, randomized clinical study. Eur Heart J Open. 2022 Sep 10;2(5):oeac057. doi: 10.1093/ehjopen/oeac057.
  • Komiyama M, Ozaki Y, Wada H, Yamakage H, Satoh-Asahara N, Kishimoto A, Katsuura Y, Imaizumi A, Hashimoto T, Sunagawa Y, Morimoto T, Hasegawa K. Study protocol to determine the effects of highly absorbable oral curcumin on the indicators of cognitive functioning: a double-blind randomised controlled trial. BMJ Open. 2022 Sep 19;12(9):e057936. doi: 10.1136/bmjopen-2021-057936.
  • Hata A, Komiyama M, Yasoda A, Wada H, Yamakage H, Satoh-Asahara N, Morimoto T, Takahashi Y, Hasegawa K. Psychological Effects of Aromatherapy on Smokers With Depressive Tendencies During Smoking Cessation Treatment: Protocol for a Pre-Post Single-Arm Clinical Trial. JMIR Res Protoc. 2022 Jul 7;11(7):e38626. doi: 10.2196/38626.
  • Masunaga N, Ogawa H, Minami K, Ishigami K, Ikeda S, Doi K, Hamatani Y, Yoshizawa T, Ide Y, Fujino A, Ishii M, Iguchi M, Wada H, Hasegawa K, Tsuji H, Esato M, Abe M, Akao M; Fushimi AF Registry Investigators. Association of Concomitant Coronary Artery Disease With Cardiovascular Events in Patients With Atrial Fibrillation　- The Fushimi AF Registry. Circ J. 2022 Jul 25;86(8):1252-1262. doi: 10.1253/circj.CJ-22-0180. Epub 2022 Jul 1.
  • Esato M, An Y, Ogawa H, Wada H, Hasegawa K, Tsuji H, Abe M, Akao M. Age-dependent risk for thromboembolism in atrial fibrillation: The Fushimi AF registry. Int J Cardiol Heart Vasc. 2022 May 19;41:101055. doi: 10.1016/j.ijcha.2022.101055.
  • Tanaka M, Yamakage H, Muranaka K, Yamada T, Araki R, Ogo A, Matoba Y, Watanabe T, Saito M, Kurita S, Yonezawa K, Tanaka T, Suzuki M, Sawamura M, Matsumoto M, Nishimura M, Kusakabe T, Wada H, Hasegawa K, Kotani K, Noda M, Satoh-Asahara N. Higher Serum Soluble TREM2 as a Potential Indicative Biomarker for Cognitive Impairment in Inadequately Controlled Type 2 Diabetes Without Obesity: The DOR-KyotoJ-1. Front Endocrinol (Lausanne). 2022 May 3;13:880148. doi: 10.3389/fendo.2022.880148.
  • Akao M, Ogawa H, Masunaga N, Minami K, Ishigami K, Ikeda S, Doi K, Hamatani Y, Yoshizawa T, Ide Y, Fujino A, Ishii M, Iguchi M, Wada H, Hasegawa K, Tsuji H, Esato M, Abe M; Fushimi AF Registry Investigators. 10-Year Trends of Antithrombotic Therapy Status and Outcomes in Japanese Atrial Fibrillation Patients　- The Fushimi AF Registry. Circ J. 2022 Mar 25;86(4):726-736. doi: 10.1253/circj.CJ-22-0023. Epub 2022 Mar 13.
  • Takai H, Sunagawa Y, Funamoto M, Shimizu K, Shimizu S, Katanasaka Y, Miyazaki Y, Imaizumi A, Hashimoto T, Wada H, Hasegawa K, Morimoto T. A Novel Curcumin Formulation, ASD-Cur, Suppressed the Development of Systolic Dysfunction After Myocardial Infarction in Rats. Eur Cardiol. 2021 Dec 14;16:e69. doi: 10.15420/ecr.2021.16.PO13.
  • Wada H, Shinozaki T, Suzuki M, Sakagami S, Ajiro Y, Funada J, Matsuda M, Shimizu M, Takenaka T, Morita Y, Yonezawa K, Matsubara H, Ono Y, Nakamura T, Fujimoto K, Ninomiya A, Kato T, Unoki T, Takagi D, Wada K, Wada M, Iguchi M, Yamakage H, Kusakabe T, Yasoda A, Shimatsu A, Kotani K, Satoh-Asahara N, Abe M, Akao M, Hasegawa K; EXCEED‐J Study Investigators. Impact of Chronic Kidney Disease on the Associations of Cardiovascular Biomarkers With Adverse Outcomes in Patients With Suspected or Known Coronary Artery Disease: The EXCEED-J Study. J Am Heart Assoc. 2022 Feb;11(3):e023464. doi: 10.1161/JAHA.121.023464. Epub 2022 Jan 20
  • Shimizu K, Sunagawa Y, Funamoto M, Honda H, Katanasaka Y, Murai N, Kawase Y, Hirako Y, Katagiri T, Yabe H, Shimizu S, Sari N, Wada H, Hasegawa K, Morimoto T. The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2-GATA4 Signaling Pathway. Pharmaceuticals (Basel). 2021 Dec 5;14(12):1268. doi: 10.3390/ph14121268.
  • Mittal S, Komiyama M, Ozaki Y, Yamakage H, Satoh-Asahara N, Yasoda A, Wada H, Funamoto M, Kana S, Miyazaki Y, Katanasaka Y, Sunagawa Y, Morimoto T, Takahashi Y, Nakayama T, Hasegawa K. Gingival bleeding and pocket depth among smokers and the related changes after short-term smoking cessation. Acta Odontol Scand. 2022 May;80(4):258-263. doi: 10.1080/00016357.2021.1995040. Epub 2021 Dec 10.
  • Ide Y, Ogawa H, Ishigami K, Ikeda S, Doi K, Hamatani Y, Fujino A, An Y, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M; Fushimi AF Registry Investigators. Clinical Characteristics and Outcomes of Very Elderly Patients With Atrial Fibrillation at High Bleeding Risk　- The Fushimi AF Registry. Circ Rep. 2021 Oct 16;3(11):629-638. doi: 10.1253/circrep.CR-21-0121.
  • Sari N, Katanasaka Y, Sugiyama Y, Sunagawa Y, Miyazaki Y, Funamoto M, Shimizu S, Shimizu K, Murakami A, Mori K, Wada H, Hasegawa K, Morimoto T. Zerumbone prevents pressure overload-induced left ventricular systolic dysfunction by inhibiting cardiac hypertrophy and fibrosis. Phytomedicine. 2021;92:153744. doi: 10.1016/j.phymed.2021.153744. Epub 2021 Sep 14.
  • Kishimoto A, Imaizumi A, Wada H, Yamakage H, Satoh-Asahara N, Hashimoto T, Hasegawa K. Newly Developed Highly Bioavailable Curcumin Formulation, curcuRougeTM, Reduces Neutrophil/Lymphocyte Ratio in the Elderly: A Double-Blind, Placebo-Controlled Clinical Trial. J Nutr Sci Vitaminol (Tokyo). 2021;67(4):249-252. doi: 10.3177/jnsv.67.249.
  • Iguchi M, Wada H, Shinozaki T, Suzuki M, Ajiro Y, Matsuda M, Koike A, Koizumi T, Shimizu M, Ono Y, Takenaka T, Sakagami S, Morita Y, Fujimoto K, Yonezawa K, Yoshida K, Ninomiya A, Nakamura T, Funada J, Kajikawa Y, Oishi Y, Kato T, Kotani K, Abe M, Akao M, Hasegawa K; PREHOSP-CHF Study Investigators. Soluble vascular endothelial growth factor receptor 2 and prognosis in patients with chronic heart failure. ESC Heart Fail. 2021 Oct;8(5):4187-4198. doi: 10.1002/ehf2.13555. Epub 2021 Aug 13.
  • Komiyama M, Ozaki Y, Miyazaki Y, Katanasaka Y, Sunagawa Y, Funamoto M, Shimizu K, Yamakage H, Sato-Asahara N, Yasoda A, Wada H, Morimoto T, Hasegawa K. Neutrophil/lymphocyte ratio is correlated with levels of inflammatory markers and is significantly reduced by smoking cessation. J Int Med Res. 2021 Jun;49(6):3000605211019223. doi: 10.1177/03000605211019223.
  • Ogawa H, An Y, Nishi H, Fukuda S, Ishigami K, Ikeda S, Doi K, Ide Y, Hamatani Y, Fujino A, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Tsukahara T, Lip GYH, Akao M. Characteristics and clinical outcomes in atrial fibrillation patients classified using cluster analysis: the Fushimi AF Registry. Europace. 2021 Sep 8;23(9):1369-1379. doi: 10.1093/europace/euab079.
  • Funamoto M, Sunagawa Y, Katanasaka Y, Shimizu K, Miyazaki Y, Sari N, Shimizu S, Mori K, Wada H, Hasegawa K, Morimoto T. Histone Acetylation Domains Are Differentially Induced during Development of Heart Failure in Dahl Salt-Sensitive Rats. Int J Mol Sci. 2021 Feb 10;22(4):1771. doi: 10.3390/ijms22041771.
  • Esato M, An Y, Ogawa H, Wada H, Hasegawa K, Tsuji H, Abe M, Akao M. Major adverse cardiovascular events and mortality after catheter ablation in Japanese patients with atrial fibrillation: The Fushimi AF Registry. Heart Vessels. 2021 Aug;36(8):1219-1227. doi: 10.1007/s00380-021-01796-0. Epub 2021 Feb 11.
  • Hamatani Y, Iguchi M, Ueno K, Aono Y, Esato M, Tsuji H, Wada H, Hasegawa K, Ogawa H, Abe M, Morita S, Akao M. Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure. Heart. 2021 May;107(9):705-712. doi: 10.1136/heartjnl-2020-317735. Epub 2020 Nov 20.
  • Wada H, Suzuki M, Matsuda M, Ajiro Y, Shinozaki T, Sakagami S, Yonezawa K, Shimizu M, Funada J, Takenaka T, Morita Y, Nakamura T, Fujimoto K, Matsubara H, Kato T, Unoki T, Takagi D, Wada K, Wada M, Iguchi M, Masunaga N, Ishii M, Yamakage H, Kusakabe T, Yasoda A, Shimatsu A, Kotani K, Satoh-Asahara N, Abe M, Akao M, Hasegawa K; ANOX Study Investigators. Impact of Smoking Status on Growth Differentiation Factor 15 and Mortality in Patients With Suspected or Known Coronary Artery Disease: The ANOX Study. J Am Heart Assoc. 2020 Nov 10:e018217. doi: 10.1161/JAHA.120.018217.
  • Ogawa H, An Y, Ishigami K, Ikeda S, Doi K, Hamatani Y, Fujino A, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M; Fushimi AF Registry investigators. Long-term clinical outcomes after major bleeding in patients with atrial fibrillation: the Fushimi AF registry. Eur Heart J Qual Care Clin Outcomes. 2021 Mar 15;7(2):163-171. doi: 10.1093/ehjqcco/qcaa082.
  • Komiyama M, Ozaki Y, Miyazaki Y, Yasoda A, Wada H, Yamakage H, Satoh-Asahara N, Morimoto T, Shimatsu A, Takahashi Y, Hasegawa K. Short-term Changes in Self-rating Depression Scale Scores after Smoking Cessation in Neurotic Patients. Intern Med. 2021 Apr 15;60(8):1175-1181. doi: 10.2169/internalmedicine.4868-20. Epub 2020 Oct 14.
  • Iguchi M, Hamatani Y, Sugiyama H, Ishigami K, Aono Y, Ikeda S, Doi K, Fujino A, An Y, Ishii M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Ogawa H, Abe M, Akao M; Fushimi AF Registry Investigators. Different Impact of Resting Heart Rate on Adverse Events in Paroxysmal and Sustained Atrial Fibrillation　- The Fushimi AF Registry. Circ J. 2020 Nov 25;84(12):2138-2147. doi: 10.1253/circj.CJ-20-0567. Epub 2020 Oct 15.
  • An Y, Ogawa H, Esato M, Ishii M, Iguchi M, Masunaga N, Fujino A, Ide Y, Hamatani Y, Doi K, Ikeda S, Ishigami K, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M; Fushimi AF Registry Investigators. Cardiovascular Events and Mortality in Patients With Atrial Fibrillation and Anemia (from the Fushimi AF Registry). Am J Cardiol. 2020 Nov 1;134:74-82. doi: 10.1016/j.amjcard.2020.08.009. Epub 2020 Aug 15.
  • Kusakabe T, Yokota S, Shimizu M, Inoue T, Tanaka M, Ohue-Kitano R, Muranaka K, Yamakage H, Wada H, Hasegawa K, Satoh-Asahara N. Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic db/db mice. BMJ Open Diabetes Res Care. 2020 Sep;8(1):e001303. doi: 10.1136/bmjdrc-2020-001303.
  • Sari N, Katanasaka Y, Honda H, Miyazaki Y, Sunagawa Y, Funamoto M, Shimizu K, Shimizu S, Wada H, Hasegawa K, Morimoto T. Cacao Bean Polyphenols Inhibit Cardiac Hypertrophy and Systolic Dysfunction in Pressure Overload-induced Heart Failure Model Mice. Planta Med. 2020 Nov;86(17):1304-1312. doi: 10.1055/a-1191-7970. Epub 2020 Jul 9.
  • Shimizu K, Sunagawa Y, Funamoto M, Wakabayashi H, Genpei M, Miyazaki Y, Katanasaka Y, Sari N, Shimizu S, Katayama A, Shibata H, Iwabuchi Y, Kakeya H, Wada H, Hasegawa K, Morimoto T. The Synthetic Curcumin Analogue GO-Y030 Effectively Suppresses the Development of Pressure Overload-induced Heart Failure in Mice. Sci Rep. 2020 Apr 28;10(1):7172. doi: 10.1038/s41598-020-64207-w.
  • Wada H, Suzuki M, Matsuda M, Ajiro Y, Shinozaki T, Sakagami S, Yonezawa K, Shimizu M, Funada J, Takenaka T, Morita Y, Nakamura T, Fujimoto K, Matsubara H, Kato T, Unoki T, Takagi D, Wada K, Wada M, Iguchi M, Masunaga N, Ishii M, Yamakage H, Kusakabe T, Yasoda A, Shimatsu A, Kotani K, Satoh-Asahara N, Abe M, Akao M, Hasegawa K; ANOX Study Investigators. Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease. J Am Heart Assoc. 2020 May 5:e015761. doi:10.1161/JAHA.119.015761. Epub 2020 Apr 22.
  • Katanasaka Y, Miyazaki Y, Sunagawa Y, Funamoto M, Shimizu K, Shimizu S, Sari N, Shimizu Y, Wada H, Hasegawa K, Morimoto T. Kosen-cha, a Polymerized Catechin-Rich Green Tea, as a Potential Functional Beverage for the Reduction of Body Weight and Cardiovascular Risk Factors: A Pilot Study in Obese Patients. Biol Pharm Bull. 2020;43(4):675-681. doi: 10.1248/bpb.b19-00921.
  • Doi K, Ogawa H, Ishigami K, Ikeda S, Aono Y, Hamatani Y, Fujino A, An Y, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Akao M; Fushimi AF Registry Investigators. Impact of Valvular Heart Disease on Mortality, Thromboembolic and Cardiac Events in Japanese Patients With Atrial Fibrillation　-The Fushimi AF Registry. Circ J. 2020 Apr 24;84(5):714-722. doi: 10.1253/circj.CJ-19-1158. Epub 2020 Mar 25.
  • Tezuka Y, Iguchi M, Hamatani Y, Ogawa H, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M; Fushimi AF Registry investigators. Association between relative wall thickness of left ventricle and incidence of thromboembolism in patients with non-valvular atrial fibrillation: The Fushimi AF Registry. Eur Heart J Qual Care Clin Outcomes. 2020 Oct 1;6(4):273-283. doi: 10.1093/ehjqcco/qcaa003.
  • Funamoto M, Shimizu K, Sunagawa Y, Katanasaka Y, Miyazaki Y, Kakeya H, Yamakage H, Satoh-Asahara N, Wada H, Hasegawa K, Morimoto T. Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus. J Diabetes Res. 2019 Nov 23;2019:8208237. doi: 10.1155/2019/8208237.
  • Funamoto M, Shimizu K, Sunagawa Y, Katanasaka Y, Miyazaki Y, Kakeya H, Yamakage H, Satoh-Asahara N, Wada H, Hasegawa K, Morimoto T. Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin- Dependent Diabetes Mellitus. J Diabetes Res. 2019 Nov 23;2019:8208237. doi: 10.1155/2019/8208237.
  • Ono K, Wada H, Satoh-Asahara N, Inoue H, Uehara K, Funada J, Ogo A, Horie T, Fujita M, Shimatsu A, Hasegawa K; ABLE-MET Investigators. Effects of Metformin on Left Ventricular Size and Function in Hypertensive Patients with Type 2 Diabetes Mellitus: Results of a Randomized, Controlled, Multicenter, Phase IV Trial. Am J Cardiovasc Drugs. 2020 Jun;20(3):283-293. doi:10.1007/s40256-019-00381-1.
  • Abe M, Masunaga N, Ishii M, Doi K, Ishigami K, Ikeda S, Aono Y, An Y, Iguchi M, Esato M, Tsuji H, Wada H, Hasegawa K, Ogawa H, Akao M; Fushimi AF Registry investigators. Current status of percutaneous coronary intervention in patients with atrial fibrillation: The Fushimi AF Registry. J Cardiol. 2020 May;75(5):513-520. doi:10.1016/j.jjcc.2019.09.014. Epub 2019 Nov 3.
  • An Y, Ogawa H, Esato M, Ishii M, Iguchi M, Masunaga N, Aono Y, Ikeda S, Doi K, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M; Fushimi AF Registry Investigators. Age-Dependent Prognostic Impact of Paroxysmal Versus Sustained Atrial Fibrillation on the Incidence of Cardiac Death and Heart Failure Hospitalization (the Fushimi AF Registry). Am J Cardiol. 2019 Nov 1;124(9):1420-1429. doi:10.1016/j.amjcard.2019.07.048. Epub 2019 Aug 7.
  • Shimizu K, Funamoto M, Sunagawa Y, Shimizu S, Katanasaka Y, Miyazaki Y, Wada H, Hasegawa K, Morimoto T. Anti-inflammatory Action of Curcumin and Its Use in the Treatment of Lifestyle-related Diseases. Eur Cardiol. 2019 Jul 11;14(2):117-122. doi: 10.15420/ecr.2019.17.2. eCollection 2019 Jul. Review.
  • Yahata K, Seta K, Kikuchi Y, Koizumi M, Murata M, Wada H, Murakami S, Ohishi M, Tsuji H; Kyoto Fushimi Renal Anemia study investigators. Treatment for renal anemia and outcomes in non-dialysis patients with chronic kidney disease: the current status of regional medicine according to the Kyoto Fushimi Renal Anemia (KFRA) study. Clin Exp Nephrol. 2019 Oct;23(10):1211-1220. doi:10.1007/s10157-019-01767-w. Epub 2019 Jul 24.
  • Genpei M, Sunagawa Y, Funamoto M, Shimizu K, Miyazaki Y, Katanasaka Y, Takahashi N, Kakeya H, Wada H, Hasegawa K, Morimoto T. Erratum to: The Inhibitory Effects of Crucumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine-Induced Responses in Cardiomyocytes. Eur Cardiol. 2018 Dec;13(2):136. doi: 10.15420/ecr.2018.13.2.ER1.
  • Wada H, Suzuki M, Matsuda M, Ajiro Y, Shinozaki T, Sakagami S, Yonezawa K, Shimizu M, Funada J, Takenaka T, Morita Y, Nakamura T, Fujimoto K, Matsubara H, Kato T, Unoki T, Takagi D, Ura S, Wada K, Iguchi M, Masunaga N, Ishii M, Yamakage H, Shimatsu A, Kotani K, Satoh-Asahara N, Abe M, Akao M, Hasegawa K for the ANOX Study Investigators. Vascular Endothelial Growth Factor-C and Mortality in Patients With Suspected or Known Coronary Artery Disease. J Am Heart Assoc. 2018;7:e010355. doi: 10.1161/JAHA.118.010355.
  • Shimada S, Komiyama M, Wada H, Yamakage H, Shimatsu A, Takahashi Y, Hasegawa K. Analysis of Factors Associated with Smoking Relapse. Eur Cardiol. 2017 Dec;12(2):111. doi: 10.15420/ecr.2017:23:20.
  • Masafumi F, Sunagawa Y, Katanasaka Y, Miyazaki Y, Wada H, Hasagawa K, Morimoto T. A Transcriptional Co-activator, p300 is Involved in the Epigenetic Gene Activation on Hypertrophic Response Gene Promoters in Heart Failure. Eur Cardiol. 2017 Dec;12(2):110. doi:10.15420/ecr.2017:23:19.
  • Genpei M, Sunagawa Y, Funamoto M, Shimizu K, Miyazaki Y, Katanasaka Y, Takahashi N, Kakeya H, Wada H, Hasegawa K, Morimoto T. The Inhibitory Effects of Crucumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine-Induced Responses in Cardiomyocytes. Eur Cardiol. 2017 Dec;12(2):107. doi:10.15420/ecr.2017:23:16.
  • Shimizu K, Funamoto M, Genpei M, Sunagawa Y, Katanasaka Y, Miyazaki Y, Shibata H, Wada H, Hasegawa K, Morimoto T. Curcumin Analogue GO-Y030 Significantly Improves Pressure Overload-induced Heart Failure in Vivo. Eur Cardiol. 2017 Dec;12(2):106. doi: 10.15420/ecr.2017:23:15.
  • Sunagawa Y, Funamoto M, Suzuki A, Shimizu K, Sakurai R, Katanasaka Y, Miyazaki Y, Asakawa T, Kan T, Inagaki J, Wada H, Hasegawa K, Morimoto T. A Novel Target Molecule of Nobiletin Derived from Citrus Peels has a Therapeutic Potency Against the Development of Heart Failure. Eur Cardiol. 2017 Dec;12(2):105. doi:10.15420/ecr.2017:23:14.
  • Komiyama M, Wada H, Yamakage H, Asahara N, Shimada S, Akao M, Morimoto T, Takahashi Y, Sawamura T, Hasegawa K. Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker. Eur Cardiol. 2017 Dec;12(2):96. doi:10.15420/ecr.2017:23:5.
  • Masunaga N, Abe M, Ogawa H, Aono Y, Ikeda S, Doi K, An Y, Ishii M, Iguchi M, Esato M, Tsuji H, Wada H, Hasegawa K, Lip GYH, Akao M; Fushimi AF Registry Investigators. Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation　- The Fushimi AF Registry.
    Circ J. 2020 Nov 25;84(12):2138-2147. doi: 10.1253/circj.CJ-20-0567. Epub 2020 Oct 15.
  • Ogawa H, An Y, Ikeda S, Aono Y, Doi K, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M; Fushimi AF Registry Investigators. Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse Events. Stroke. 2018 Oct;49(10):2301-2308. doi: 10.1161/STROKEAHA.118.021396.
  • Komiyama M, Ozaki Y, Wada H, Yamakage H, Satoh-Asahara N, Morimoto T, Shimatsu A, Takahashi Y, Hasegawa K. The effects of dietary instruction on cardiovascular risk markers after smoking cessation: study protocol for a multicenter randomized controlled trial in Japan. Trials. 2018 Oct 4;19(1):538. doi:10.1186/s13063-018-2919-6.
  • Komiyama M, Wada H, Yamakage H, Satoh-Asahara N, Sunagawa Y, Morimoto T, Ozaki Y, Shimatsu A, Takahashi Y, Hasegawa K. Analysis of changes on adiponectin levels and abdominal obesity after smoking cessation. PLoS One. 2018 Aug 7;13(8):e0201244. doi: 10.1371/journal.pone.0201244.
  • An Y, Ogawa H, Yamashita Y, Ishii M, Iguchi M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M; Fushimi AF Registry investigators.Causes of death in Japanese patients with atrial fibrillation: The Fushimi AF Registry. Eur Heart J Qual Care Clin Outcomes. 2018 Jul 18. doi:10.1093/ehjqcco/qcy033.
  • An Y, Esato M, Ishii M, Iguchi M, Masunaga N, Tsuji H, Wada H, Hasegawa K, Ogawa H, Abe M, Lip GYH, Akao M. Correction to: Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy: the Fushimi AF Registry. Heart Vessels. 2018 Jun 27. doi:10.1007/s00380-018-1212-7.
  • Komiyama M, Miyazaki Y, Wada H, Iguchi M, Abe M, Ogawa H, Akao M, Yamakage H, Satoh-Asahara N, Sunagawa Y, Morimoto T, Hasegawa K. A study on indices of apixaban anticoagulation: A single-center prospective study. J Pharmacol Sci.2018 Jun;137(2):105-109. doi: 10.1016/j.jphs.2018.05.001.
  • Tanaka M, Masuda S, Yamakage H, Inoue T, Ohue-Kitano R, Yokota S, Kusakabe T, Wada H, Sanada K, Ishii K, Hasegawa K, Shimatsu A, Satoh-Asahara N. Role of serum myostatin in the association between hyperinsulinemia and muscle atrophy in Japanese obese patients. Diabetes Res Clin Pract. 2018 Aug;142:195-202. doi: 10.1016/j.diabres.2018.05.041.
  • An Y, Esato M, Ishii M, Iguchi M, Masunaga N, Tsuji H, Wada H, Hasegawa K, Ogawa H, Abe M, Lip GYH, Akao M. Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy: the Fushimi AF Registry. Heart Vessels. 2018 May 24. doi:10.1007/s00380-018-1194-5.
  • Sunagawa Y, Funamoto M, Sono S, Shimizu K, Shimizu S, Genpei M, Miyazaki Y, Katanasaka Y, Morimoto E, Ueno M, Komiyama M, Kakeya H, Wada H, Hasegawa K, Morimoto T. Curcumin and its demethoxy derivatives possess p300 HAT inhibitory activity and suppress hypertrophic responses in cardiomyocytes. J Pharmacol Sci. 2018 Apr;136(4):212-217. doi: 10.1016/j.jphs.2017.12.013.
  • Iguchi M, Tezuka Y, Ogawa H, Hamatani Y, Takagi D, An Y, Unoki T, Ishii M, Masunaga N, Esato M, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GYH, Akao M. Incidence and Risk Factors of Stroke or Systemic Embolism in Patients With Atrial Fibrillation and Heart Failure　- The Fushimi AF Registry. Circ J. 2018 Apr 25;82(5):1327-1335. doi:10.1253/circj.CJ-17-1155.
  • Sunagawa Y, Okamura N, Miyazaki Y, Shimizu K, Genpei M, Funamoto M, Shimizu S,Katanasaka Y, Morimoto E, Yamakage H, Komiyama M, Satoh-Asahara N, Wada H, Suzuki M, Hasegawa K, Morimoto T. Effects of products containing Bacillus subtilis var natto on healthy subjects with neck and shoulder stiffness, a double-blind,placebo-controlled, randomized crossover study. Biol Pharm Bull. 2018 Feb 6. doi: 10.1248/bpb.b17-00780.
  • Komiyama M, Takanabe R, Ono K, Shimada S, Wada H, Yamakage H, Satoh-Asahara N,Morimoto T, Shimatsu A, Takahashi Y, Hasegawa K. Association between monocyte chemoattractant protein-1 and blood pressure in smokers. J Int Med Res. 2018 Mar;46(3):965-974. doi: 10.1177/0300060517723415.
  • Esato M, Chun YH, An Y, Ogawa H, Wada H, Hasegawa K, Tsuji H, Abe M, Lip GYH, Akao M. Clinical Impact of Asymptomatic Presentation Status in Patients With Paroxysmal and Sustained Atrial Fibrillation: The Fushimi AF Registry. Chest. 2017 Dec;152(6):1266-1275. doi: 10.1016/j.chest.2017.08.004.
  • Tanaka M, Yamakage H, Masuda S, Inoue T, Ohue-Kitano R, Araki R, Matoba Y, Saito M, Nagaoka T, Yonezawa K, Tanaka T, Suzuki M, Sawamura M, Nishimura M, Odori S, Wada H, Kotani K, Kusakabe T, Shimatsu A, Hasegawa K, Satoh-Asahara N. Serum soluble TREM2 is a potential novel biomarker of cognitive impairment in Japanese non-obese patients with diabetes. Diabetes Metab. 2017 Jul 31. pii: S1262-3636(17)30470-6. doi: 10.1016/j.diabet.2017.06.006.
  • Komiyama M, Wada H, Ono K, Yamakage H, Satoh-Asahara N, Shimada S, Akao M, Morimoto T, Shimatsu A, Takahashi Y, Sawamura T, Hasegawa K. Smoking cessation reduces the lectin-like low-density lipoprotein receptor index, an independent cardiovascular risk marker of vascular inflammation. Heart Vessels. 2018 Jan;33(1):9-16. doi: 10.1007/s00380-017-1026-z.
  • Ishii M, Ogawa H, Unoki T, An Y, Iguchi M, Masunaga N, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Akao M. Relationship of Hypertension and Systolic Blood Pressure With the Risk of Stroke or Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry. Am J Hypertens. 2017 Nov 1;30(11):1073-1082. doi: 10.1093/ajh/hpx094.
  • Ogawa H, Hamatani Y, Doi K, Tezuka Y, An Y, Ishii M, Iguchi M, Masunaga N, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Lip G, Akao M. Gender-related differences in clinical events of patients with atrial fibrillation: The Fushimi AF Registry. Circ J. 2017 Sep 25;81(10):1403-1410. doi: 10.1253/circj.CJ-17-0071.
  • Yamashita Y, Uozumi R, Hamatani Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Ogawa H, Abe M, Morita S, Akao M. Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients　- Fushimi AF Registry. Circ J. 2017 Aug 25;81(9):1278-1285. doi: 10.1253/circj.CJ-16-1337.
  • Inoue T, Tanaka M, Masuda S, Ohue-Kitano R, Yamakage H, Muranaka K, Wada H, Kusakabe T, Shimatsu A, Hasegawa K, Satoh-Asahara N. Omega-3 polyunsaturated fatty acids suppress the inflammatory responses of lipopolysaccharide-stimulated mouse microglia by activating SIRT1 pathways. Biochim Biophys Acta. 2017 Feb 22;1862(5):552-560. doi: 10.1016/j.bbalip.2017.02.010.
  • Abe M, Ogawa H, Ishii M, Masunaga N, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Lip GY, Akao M. Relation of Stroke and Major Bleeding to Creatinine Clearance in Patients With Atrial Fibrillation (from the Fushimi AF Registry). Am J Cardiol. 2017 Apr 15;119(8):1229-1237. doi:10.1016/j.amjcard.2017.01.005.
  • Komiyama M, Shimada S, Wada H, Yamakage H, Satoh-Asahara N, Shimatsu A, Akao M, Morimoto T, Takahashi Y, Hasegawa K. Time-dependent Changes of Atherosclerotic LDL Complexes after Smoking Cessation. J Atheroscler Thromb. 2016 Nov 1;23(11):1270-1275.
  • Miyazaki Y, Katanasaka Y, Sunagawa Y, Hirano-Sunagawa S, Funamoto M, Morimoto E, Komiyama M, Shimatsu A, Satoh-Asahara N, Yamakage H, Wada H, Hasegawa K, Morimoto T. Effect of statins on atherogenic serum amyloid A and α1-antitrypsin low-density lipoprotein complexes. Int J Cardiol. 2016 Dec 15;225:332-336. doi:10.1016/j.ijcard.2016.09.116.
  • Funamoto M, Sunagawa Y, Katanasaka Y, Miyazaki Y, Imaizumi A, Kakeya H, Yamakage H, Satoh-Asahara N, Komiyama M, Wada H, Hasegawa K, Morimoto T. Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD. Int J Chron Obstruct Pulmon Dis. 2016 Aug 26;11:2029-34. doi:10.2147/COPD.S104490.
  • Hamatani Y, Ogawa H, Takabayashi K, Yamashita Y, Takagi D, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GY, Akao M. Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Sci Rep. 2016 Aug 3;6:31042. doi:10.1038/srep31042.
  • Suzuki H, Katanasaka Y, Sunagawa Y, Miyazaki Y, Funamoto M, Wada H, Hasegawa K, Morimoto T. Tyrosine phosphorylation of RACK1 triggers cardiomyocyte hypertrophy by regulating the interaction between p300 and GATA4. Biochim Biophys Acta. 2016 Sep;1862(9):1544-57. doi: 10.1016/j.bbadis.2016.05.006.
  • Tanaka M, Masuda S, Matsuo Y, Sasaki Y, Yamakage H, Muranaka K, Wada H, Hasegawa K, Tsukahara T, Shimatsu A, Satoh-Asahara N. Hyperglycemia and Inflammatory Property of Circulating Monocytes are Associated with Inflammatory Property of Carotid Plaques in Patients Undergoing Carotid Endarterectomy. J Atheroscler Thromb. 2016 Oct 1;23(10):1212-1221.
  • Yamashita Y, Takagi D, Hamatani Y, Iguchi M, Masunaga N, Esato M, Chun YH, Itoh H, Nishimura M, Wada H, Hasegawa K, Ogawa H, Abe M, Akao M. Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry. Heart Vessels. 2016 Dec;31(12):2025-2034.
  • Sunagawa Y, Katanasaka Y, Wada H, Hasegawa K, Morimoto T. [Functional Analysis of GATA4 Complex, a Cardiac Hypertrophy-response Transcriptional Factor, Using a Proteomics Approach]. Yakugaku Zasshi. 2016;136(2):151-6. doi:10.1248/yakushi.15-00226-2. Review. Japanese. PubMed PMID: 26831785.
  • Tanaka M, Matsuo Y, Yamakage H, Masuda S, Terada Y, Muranaka K, Wada H, Hasegawa K, Shimatsu A, Satoh-Asahara N. Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects. Metabolism. 2016 Feb;65(2):1-11. doi: 10.1016/j.metabol.2015.10.009.
  • Hamatani Y, Yamashita Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GY, Akao M. Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The Fushimi AF Registry. PLoS One. 2015 Nov 5;10(11):e0142394. doi: 10.1371/journal.pone.0142394.
  • Takabayashi K, Hamatani Y, Yamashita Y, Takagi D, Unoki T, Ishii M, Iguchi M, Masunaga N, Ogawa H, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GY, Akao M. Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation: The Fushimi Atrial Fibrillation Registry. Stroke. 2015 Dec;46(12):3354-61. doi: 10.1161/STROKEAHA.115.010947.
  • Morimoto T, Katanasaka Y, Sunagawa Y, Hirano S, Miyazaki Y, Funamoto M, Hojo Y, Suzuki H, Morimoto E, Ueno M, Shimatsu A, Satoh-Asahara N, Yamakage H, Wada H, Hasegawa K. Effects of Statins on Left Ventricular Diastolic Function in Patients with Dyslipidemia and Diastolic Dysfunction (Stat-LVDF Study). Biol Pharm Bull. 2015;38(9):1404-9. doi: 10.1248/bpb.b15-00126.
  • Yamashita Y, Hamatani Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GY, Akao M. Clinical Characteristics and Outcomes in Extreme Elderly (Age ≥ 85 Years) Japanese Patients With Atrial Fibrillation: The Fushimi AF Registry. Chest. 2016 Feb;149(2):401-12. doi: 10.1378/chest.15-1095.
  • Yamashita Y, Unoki T, Takagi D, Hamatani Y, Ishii M, Iguchi M, Ogawa H, Masunaga N, Wada H, Hasegawa K, Abe M, Akao M. Indications, applications, and outcomes of inferior vena cava filters for venous thromboembolism in Japanese patients. Heart Vessels. 2016 Jul;31(7):1084-90. doi: 10.1007/s00380-015-0709-6.
  • Sunagawa Y, Hirano S, Katanasaka Y, Miyazaki Y, Funamoto M, Okamura N, Hojo Y, Suzuki H, Doi O, Yokoji T, Morimoto E, Takashi T, Ozawa H, Imaizumi A, Ueno M, Kakeya H, Shimatsu A, Wada H, Hasegawa K, Morimoto T. Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study. J Nutr Sci Vitaminol (Tokyo). 2015;61(1):37-44.
  • Hamatani Y, Ogawa H, Uozumi R, Iguchi M, Yamashita Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Morita S, Akao M. Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients - Insight From the Fushimi AF Registry. Circ J. 2015;79(5):1009-17. doi:10.1253/circj.CJ-14-1245.
  • Sunagawa Y, Sono S, Katanasaka Y, Funamoto M, Hirano S, Miyazaki Y, Hojo Y, Suzuki H, Morimoto E, Marui A, Sakata R, Ueno M, Kakeya H, Wada H, Hasegawa K, Morimoto T. Optimal dose-setting study of curcumin for improvement of left ventricular systolic function after myocardial infarction in rats. J Pharmacol Sci. 2014;126(4):329-36. doi: 10.1254/jphs.14151FP.
  • Ito R, Yamakage H, Kotani K, Wada H, Otani S, Yonezawa K, Ogo A, Okajima T, Adachi M, Araki R, Yoshida K, Saito M, Nagaoka T, Toyonaga T, Tanaka T, Yamada T, Ota I, Oishi M, Miyanaga F, Shimatsu A, Satoh-Asahara N; Japan Diabetes and Obesity Study (J-DOS) Group.. Comparison of cystatin C- and creatinine-based estimated glomerular filtration rate to predict coronary heart disease risk in Japanese patients with obesity and diabetes. Endocr J. 2015;62(2):201-7. doi:10.1507/endocrj.EJ14-0352.
  • Watanabe S, Horie T, Nagao K, Kuwabara Y, Baba O, Nishi H, Sowa N, Narazaki M, Matsuda T, Takemura G, Wada H, Hasegawa K, Kimura T, Ono K. Cardiac-specific inhibition of kinase activity in calcium/calmodulin-dependent protein kinase kinase-β leads to accelerated left ventricular remodeling and heart failure after transverse aortic constriction in mice. PLoS One. 2014 Sep 25;9(9):e108201. doi: 10.1371/journal.pone.0108201.
  • Komiyama M, Wada H, Ura S, Yamakage H, Satoh-Asahara N, Shimada S, Akao M, Koyama H, Kono K, Shimatsu A, Takahashi Y, Hasegawa K. The effects of weight gain after smoking cessation on atherogenic α1-antitrypsin-low-density lipoprotein. Heart Vessels. 2015 Nov;30(6):734-9. doi: 10.1007/s00380-014-0549-9.
  • Akao M, Chun YH, Esato M, Abe M, Tsuji H, Wada H, Hasegawa K; Fushimi AF Registry Investigators.. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014;78(9):2166-72.
  • Komiyama M, Wada H, Hasegawa K. Matters of controversy regarding lipid therapy for Japanese patients with coronary artery disease. Intern Med. 2014;53(8):817-8.
  • Hayama M, Inoue H, Wada H, Mio T. Massive haemoptysis following dabigatran administration in a patient with bronchiectasis. BMJ Case Rep. 2014 Feb 19;2014. pii: bcr2013201001. doi: 10.1136/bcr-2013-201001..
  • Ito R, Satoh-Asahara N, Yamakage H, Sasaki Y, Odori S, Kono S, Wada H, Suganami T, Ogawa Y, Hasegawa K, Shimatsu A. An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia. J Atheroscler Thromb. 2014;21(3):248-60.
  • Morimoto T, Sunagawa Y, Katanasaka Y, Hirano S, Namiki M, Watanabe Y, Suzuki H, Doi O, Suzuki K, Yamauchi M, Yokoji T, Miyoshi-Morimoto E, Otsuka Y, Hamada T, Imaizumi A, Nonaka Y, Fuwa T, Teramoto T, Kakeya H, Wada H, Hasegawa K. Drinkable preparation of Theracurmin exhibits high absorption efficiency--a single-dose, double-blind, 4-way crossover study. Biol Pharm Bull. 2013;36(11):1708-14.
  • Komiyama M, Wada H, Ura S, Yamakage H, Satoh-Asahara N, Shimatsu A, Koyama H, Kono K, Takahashi Y, Hasegawa K. Analysis of factors that determine weight gain during smoking cessation therapy. PLoS One. 2013 Aug 21;8(8):e72010. doi:10.1371/journal.pone.0072010.
  • Satoh-Asahara N, Shimatsu A, Wada H, Suganami T, Hasegawa K, Ogawa Y. Response to Comment on: Satoh-Asahara et al. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care 2012;35:2631-2639. Diabetes Care. 2013 Jul;36(7):e110. doi: 10.2337/dc13-0376.
  • Takanabe-Mori R, Ono K, Wada H, Takaya T, Ura S, Yamakage H, Satoh-Asahara N, Shimatsu A, Takahashi Y, Fujita M, Fujita Y, Sawamura T, Hasegawa K. Lectin-like oxidized low-density lipoprotein receptor-1 plays an important role in vascular inflammation in current smokers. J Atheroscler Thromb. 2013;20(6):585-90..
  • Akao M, Chun YH, Wada H, Esato M, Hashimoto T, Abe M, Hasegawa K, Tsuji H, Furuke K; Fushimi AF Registry Investigators.. Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. J Cardiol. 2013 Apr;61(4):260-6. doi:10.1016/j.jjcc.2012.12.002.
  • Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, Odori S, Kono S, Hasegawa K, Shimatsu A. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism. 2013 Mar;62(3):347-51. doi: 10.1016/j.metabol.2012.09.004.
  • Satoh-Asahara N, Shimatsu A, Sasaki Y, Nakaoka H, Himeno A, Tochiya M, Kono S, Takaya T, Ono K, Wada H, Suganami T, Hasegawa K, Ogawa Y. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care. 2012 Dec;35(12):2631-9. doi: 10.2337/dc12-0269.
  • Sowa N, Horie T, Kuwabara Y, Baba O, Watanabe S, Nishi H, Kinoshita M, Takanabe-Mori R, Wada H, Shimatsu A, Hasegawa K, Kimura T, Ono K. MicroRNA 26b encoded by the intron of small CTD phosphatase (SCP) 1 has an antagonistic effect on its host gene. J Cell Biochem. 2012 Nov;113(11):3455-65. doi:10.1002/jcb.24222.
  • Sunagawa Y, Wada H, Suzuki H, Sasaki H, Imaizumi A, Fukuda H, Hashimoto T, Katanasaka Y, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K, Morimoto T. A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure after myocardial infarction in rats. Biol Pharm Bull. 2012;35(2):139-44.
  • Wada H, Ura S, Kitaoka S, Satoh-Asahara N, Horie T, Ono K, Takaya T, Takanabe-Mori R, Akao M, Abe M, Morimoto T, Murayama T, Yokode M, Fujita M, Shimatsu A, Hasegawa K. Distinct characteristics of circulating vascular endothelial growth factor-a and C levels in human subjects. PLoS One. 2011;6(12):e29351. doi: 10.1371/journal.pone.0029351.
  • Wada H, Ura S, Satoh-Asahara N, Kitaoka S, Mashiba S, Akao M, Abe M, Ono K, Morimoto T, Fujita M, Shimatsu A, Takahashi Y, Hasegawa K. α1-Antitrypsin low-density-lipoprotein serves as a marker of smoking-specific oxidative stress. J Atheroscler Thromb. 2012;19(1):47-58.
  • Himeno A, Satoh-Asahara N, Usui T, Wada H, Tochiya M, Kono S, Yamada-Goto N, Katsuura G, Hasegawa K, Nakao K, Shimatsu A. Salivary cortisol levels are associated with outcomes of weight reduction therapy in obese Japanese patients. Metabolism. 2012 Feb;61(2):255-61. doi: 10.1016/j.metabol.2011.06.023.
  • Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S, Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J. 2011;75(9):2151-9.
  • Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660-5.
  • Nishi H, Ono K, Horie T, Nagao K, Kinoshita M, Kuwabara Y, Watanabe S, Takaya T, Tamaki Y, Takanabe-Mori R, Wada H, Hasegawa K, Iwanaga Y, Kawamura T, Kita T, Kimura T. MicroRNA-27a regulates beta cardiac myosin heavy chain gene expression by targeting thyroid hormone receptor beta1 in neonatal rat ventricular myocytes. Mol Cell Biol. 2011 Feb;31(4):744-55. doi: 10.1128/MCB.00581-10.
  • Shimada S, Hasegawa K, Wada H, Terashima S, Satoh-Asahara N, Yamakage H, Kitaoka S, Akao M, Shimatsu A, Takahashi Y. High blood viscosity is closely associated with cigarette smoking and markedly reduced by smoking cessation. Circ J. 2011;75(1):185-9.
  • Takanabe-Mori R, Ono K, Sowa N, Wada H, Takaya T, Horie T, Satoh-Asahara N, Shimatsu A, Fujita M, Sawamura T, Hasegawa K. Lectin-like oxidized low-density lipoprotein receptor-1 is required for the adipose tissue expression of proinflammatory cytokines in high-fat diet-induced obese mice. Biochem Biophys Res Commun. 2010 Jul 30;398(3):576-80. doi: 10.1016/j.bbrc.2010.06.123.
  • Takaya T, Wada H, Morimoto T, Sunagawa Y, Kawamura T, Takanabe-Mori R, Shimatsu A, Fujita Y, Sato Y, Fujita M, Kimura T, Sawamura T, Hasegawa K. Left ventricular expression of lectin-like oxidized low-density lipoprotein receptor-1 in failing rat hearts. Circ J. 2010 Apr;74(4):723-9.
  • Wada H, Shinjo D, Kameda S, Ono K, Satoh N, Morimoto T, Osakada G, Nakano T, Fujita M, Shimatsu A, Hasegawa K. Transmitral E/A ratio decreases in association with abdominal fat accumulation in patients with impaired glucose tolerance or mild diabetes without left ventricular hypertrophy. Heart Vessels. 2010 Jan;25(1):45-50. doi: 10.1007/s00380-009-1152-3.
  • Sunagawa Y, Morimoto T, Takaya T, Kaichi S, Wada H, Kawamura T, Fujita M, Shimatsu A, Kita T, Hasegawa K. Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes. J Biol Chem. 2010 Mar 26;285(13):9556-68. doi:10.1074/jbc.M109.070458.
  • Yoshida Y, Morimoto T, Takaya T, Kawamura T, Sunagawa Y, Wada H, Fujita M, Shimatsu A, Kita T, Hasegawa K. Aldosterone signaling associates with p300/GATA4 transcriptional pathway during the hypertrophic response of cardiomyocytes. Circ J. 2010 Jan;74(1):156-62.
  • Wada H, Satoh N, Kitaoka S, Ono K, Morimoto T, Kawamura T, Nakano T, Fujita M, Kita T, Shimatsu A, Hasegawa K. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. Atherosclerosis. 2010 Feb;208(2):512-7. doi:10.1016/j.atherosclerosis.2009.07.045.
  • Satoh N, Kotani K, Wada H, Himeno A, Shimada S, Sasaki Y, Yamada K, Shimatsu A, Hasegawa K. Unfavorable blood rheology is closely associated with arterial stiffness in obese patients. Endocr J. 2009;56(7):915-8. PubMed PMID: 19550074.
  • Takaya T, Ono K, Kawamura T, Takanabe R, Kaichi S, Morimoto T, Wada H, Kita T, Shimatsu A, Hasegawa K. MicroRNA-1 and MicroRNA-133 in spontaneous myocardial differentiation of mouse embryonic stem cells. Circ J. 2009 Aug;73(8):1492-7.
  • Takanabe R, Ono K, Abe Y, Takaya T, Horie T, Wada H, Kita T, Satoh N, Shimatsu A, Hasegawa K. Up-regulated expression of microRNA-143 in association with obesity in adipose tissue of mice fed high-fat diet. Biochem Biophys Res Commun. 2008 Nov 28;376(4):728-32. doi: 10.1016/j.bbrc.2008.09.050.
  • Morimoto T, Fujita M, Kawamura T, Sunagawa Y, Takaya T, Wada H, Shimatsu A, Kita T, Hasegawa K. Myocardial regulation of p300 and p53 by doxorubicin involves ubiquitin pathways. Circ J. 2008 Sep;72(9):1506-11.
  • Wada H, Abe M, Ono K, Morimoto T, Kawamura T, Takaya T, Satoh N, Fujita M,Kita T, Shimatsu A, Hasegawa K. Statins activate GATA-6 and induce differentiated vascular smooth muscle cells. Biochem Biophys Res Commun. 2008 Oct 3;374(4):731-6. doi: 10.1016/j.bbrc.2008.07.098.
  • Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, Jeltsch M, Juan TD, Sievers RE, Chorianopoulos E, Wada H, Vanwildemeersch M, Noel A, Foidart JM, Springer ML, von Degenfeld G, Dewerchin M, Blau HM, Alitalo K, Eriksson U, Carmeliet P, Moons L. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1614-20. doi: 10.1161/ATVBAHA.107.158725.
  • Satoh N, Wada H, Ono K, Yamakage H, Yamada K, Nakano T, Hattori M, Shimatsu A, Kuzuya H, Hasegawa K. Small dense LDL-cholesterol relative to LDL-cholesterol is a strong independent determinant of hypoadiponectinemia in metabolic syndrome. Circ J. 2008 Jun;72(6):932-9.
  • Horie T, Ono K, Kinoshita M, Nishi H, Nagao K, Kawamura T, Abe Y, Wada H, Shimatsu A, Kita T, Hasegawa K. TG-interacting factor is required for the differentiation of preadipocytes. J Lipid Res. 2008 Jun;49(6):1224-34. doi:10.1194/jlr.M700578-JLR200.
  • Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda M, Fujita M, Shimatsu A, Kita T, Hasegawa K. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest. 2008 Mar;118(3):868-78. doi: 10.1172/JCI33160.
  • Horie T, Ono K, Nagao K, Nishi H, Kinoshita M, Kawamura T, Wada H, Shimatsu A, Kita T, Hasegawa K. Oxidative stress induces GLUT4 translocation by activation of PI3-K/Akt and dual AMPK kinase in cardiac myocytes. J Cell Physiol. 2008 Jun;215(3):733-42. doi: 10.1002/jcp.21353.
  • Hosseinkhani M, Hasegawa K, Ono K, Kawamura T, Takaya T, Morimoto T, Wada H, Shimatsu A, Prat SG, Suemori H, Nakatsuji N, Kita T. Trichostatin A induces myocardial differentiation of monkey ES cells. Biochem Biophys Res Commun. 2007 May 4;356(2):386-91.
  • Abe Y, Ono K, Kawamura T, Wada H, Kita T, Shimatsu A, Hasegawa K. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2387-96.
  • Miyamoto S, Kawamura T, Morimoto T, Ono K, Wada H, Kawase Y, Matsumori A, Nishio R, Kita T, Hasegawa K. Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation. 2006 Feb 7;113(5):679-90.
  • Kawamura T, Ono K, Morimoto T, Wada H, Hirai M, Hidaka K, Morisaki T, Heike T, Nakahata T, Kita T, Hasegawa K. Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes. J Biol Chem. 2005 May 20;280(20):19682-8.

邦文誌（10件）

  • 和田　啓道、井口　守丈、長谷川　浩二
    NHO研究ネットワークグル－プの活動とNHOブランディングへの貢献
    － 心脳大血管グループ（循環器サブグループ）10年の歩み－
    Activity of the NHO Research Network Group and Its Contribution to the Branding of NHO:The 10-Year History of Cardio-Cerebrovascular Group (Cardiology Subgroup)
    IRYO 2023; 77(5): 324-330.
  • 和田　啓道
    冠動脈疾患疑い患者におけるVEGF-Cレベルと死亡リスクの関連.
    循環器専門医 2018; 27: 49-53.
  • 尾崎　裕香、高橋　裕子、小見山　麻紀、和田　啓道、浅原　哲子、山陰　一、船本　雅文、砂川　陽一、森本　達也、飯田　真美、大和　浩、藤原　久義、長谷川　浩二.
    受動喫煙の健康被害と全面禁煙に関する日米アンケート比較調査 ―喫煙状況別解析―. 禁煙科学2016; 10: 13-26.
  • 赤尾　昌治、阿部　充、江里　正弘、前　栄和、和田　啓道、長谷川　浩二
    血液透析中の心房細動症例の抗凝固療法について：診療現場の実態　日本血栓止血学会誌　2013; 24(3): 290-294.
  • 飯塚　三枝子、和田　啓道、中村　道三.
    若年性アルツハイマー病に対する外来音楽療法の試み　
    －フラッシュソングセラピーを用いて－ 音楽医療研究 2012 Nov 19, in press
  • 長谷川　浩二、和田　啓道、高橋　裕子.
    タバコ, 潜在性うつ状態と心血管疾患.
    循環器専門医 2010; 18(2): 352-356.
  • 和田　啓道、長谷川　浩二、寺嶋　幸子、佐藤　哲子、井上　美鈴、飯田　夕子、山陰　一、北岡　修二、森本　達也、藤田　正俊、島津　章、高橋　裕子.
    初診時SDSスコアは禁煙達成成否の強い独立決定因子である. 禁煙科学2008; 4: 4-8.
  • 和田　啓道、長谷川　浩二、寺嶋　幸子、伊藤　知明、飯田　夕子、北岡　修二、佐藤　哲子、中野　為夫、島津　章、高橋　裕子.
    喫煙の健康への影響に関する知識と関心度 アンケート調査. 禁煙科学2008; 3: 5-10.
  • 長谷川　浩二、寺嶋　幸子、佐藤　哲子、井上　美鈴、和田　啓道、伊藤　知明、飯田　夕子、山陰　一、島津　章、高橋　裕子.
    禁煙外来初診患者におけるうつ状態の調査. 禁煙科学2008; 2: 23-26.
  • 和田　啓道、北　徹、長谷川　浩二
    自家骨髄単核球と血管・心筋再生療法 (急性心筋梗塞). Pharma Medica 2005;23(10):19-23

書籍（6件）

  • 和田　啓道
    末梢動脈疾患「分かりやすい内科学（井村裕夫 編集主幹）文光堂」2023;2:219-225. (第2章 循環器疾患)
  • 和田　啓道
    観察研究での統計解析 「これが伏見流！心房細動の診かた、全力でわかりやすく教えます（赤尾　昌治 編）」2017: 221-225 (第5章Lesson 8).
  • 和田　啓道
    静脈疾患「分かりやすい内科学（井村裕夫 編集主幹）文光堂」2014;2:224-226. (第2章 循環器疾患)
  • 和田　啓道
    大動脈縮窄圧負荷心肥大モデル「循環器疾患 : 疾患モデルの作製と利用 (Seriesモデル動物利用マニュアル) 北徹, 堀内久徳, 柳田素子, 猪原匡史, 冨本秀和, 並河徹 編 エル・アイ・シー」2010;8:49-52 (第4節)
  • 和田　啓道、長谷川　浩二
    心疾患の検査（心筋梗塞・狭心症）「チームで撲滅!メタボリックシンドローム（島津　章、浅原　哲子編）診断と治療社」2009 (上級編)
  • 和田　啓道、長谷川　浩二
    冠動脈疾患（心筋梗塞・狭心症）「チームで撲滅!メタボリックシンドローム（島津　章、浅原　哲子編）診断と治療社」2009 (基礎編)

→先端医療技術開発研究室 (心血管リスクとバイオマーカー研究グループ)